.

Karyopharm Therapeutics reported $939K in Cost of Sales for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cost Of Sales Change
TG Therapeutics TGTX:US 23K 214K
Abbott ABT:US $ 4933M 54M
Abbvie ABBV:US $ 4142M 121M
Amgen AMGN:US $ 1510M 51M
AstraZeneca AZN:LN 156386.94M 17145.23M
Astrazeneca AZN:US 1.9B 375M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
Bristol Myers Squibb BMY:US $ 2677M 206M
Eli Lilly And LLY:US $ 1430.5M 641.6M
Epizyme EPZM:US $ 5.17M 2.53M
GlaxoSmithKline GSK:LN 213600M 55400M
Johnson & Johnson JNJ:US $ 7919M 321M
Karyopharm Therapeutics KPTI:US $ 939K 487K
MacroGenics MGNX:US 2.4M 2.35M
Merk MRK:US $ 3698M 1636M
Nektar Therapeutics NKTR:US $ 5.12M 0.2M
Novartis NOVN:VX SF 3749M 6M
Novartis NVS:US $ 3749M 6M
Pfizer PFE:US $ 8671M 1339M
Regeneron Pharmaceuticals REGN:US $ 297.1M 107.8M
Takeda 4502:JP Y 292882M 15498M
Ultragenyx Pharmaceutical RARE:US $ 8.27M 2.17M
YTE INCY:US $ 45.24M 8.02M